Research programme: non-nucleoside reverse transcriptase inhibitors - Bristol-Myers Squibb

Drug Profile

Research programme: non-nucleoside reverse transcriptase inhibitors - Bristol-Myers Squibb

Alternative Names: DPC-A78277; NNRTIs research programme - Bristol-Myers Squibb; Research programme: NNRTIs - Bristol-Myers Squibb

Latest Information Update: 26 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 26 Sep 2005 Discontinued - Preclinical for HIV infections treatment in USA (unspecified route)
  • 22 Sep 2005 Data presented at the 230th American Chemistry Society National Meeting (230th-ACS-2005) have been added to the Viral infections antimicrobial section
  • 07 Jun 2001 Preclinical trials in HIV infections treatment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top